Scientists from Scripps Research Translational Institute in La Jolla, California found that people who use Paxlovid are twice as likely to suffer a COVID-19 rebound as their peers.Scientists from Scripps Research Translational Institute in La Jolla, California found that people who use Paxlovid are twice as likely to suffer a COVID-19 rebound as their peers.Read MoreHealth News | Mail Online